
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, DC 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported)
December 17, 2014**

Pacific Biosciences of California, Inc.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-34899
(Commission
File Number)

16-1590339
(IRS Employer
Identification No.)

1380 Willow Road
Menlo Park, California 94025
(Address of principal executive offices, including zip code)

(650) 521-8000
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS

On December 17, 2014, the board of directors (the “Board”) of Pacific Biosciences of California, Inc. (the “Company”) appointed Kathy Ordoñez, age 64, as a Class III director to serve on the Board effective immediately.

Ms. Ordoñez served as the Senior Vice President of Diagnostic Solutions of Quest Diagnostics, Inc., a publicly-traded company that provides clinical laboratory services, from May of 2011 to June of 2013. She previously served in various roles, including Chief Executive Officer, at Celera Corporation, a publicly traded biotechnology company, until its sale to Quest Diagnostics in 2011. Ms. Ordoñez also previously held several senior positions at Hoffmann-La Roche, overseeing the formation of Roche Molecular Systems where she served as President and Chief Executive Officer. Ms. Ordoñez also previously served on the board of AdvaMed, a medical device and diagnostics industry advocacy group. Ms. Ordoñez holds a B.A. in Chemistry and Physics and a Doctorate of Science (Honorary) from Hartwick College

As previously disclosed in the Company’s proxy statement for the 2014 Annual Meeting of Stockholders, as a non-employee director, Ms. Ordoñez will receive an annual retainer of \$35,000. Pursuant to the Company’s outside director equity compensation policy, Ms. Ordoñez was automatically granted a stock option to purchase 35,000 shares of the Company’s common stock on the date of her appointment to the Board.

ITEM 7.01. REGULATION FD DISCLOSURE

On December 18, 2014, the Company issued a press release announcing the appointment of Ms. Ordoñez to the Board. A copy of the press release is included as Exhibit 99.1. This information is intended to be furnished under Item 7.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press release dated December 18, 2014 titled “Pacific Biosciences Appoints Kathy Ordoñez to Board of Directors” (furnished and not filed herewith solely pursuant to Item 7.01).

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press release dated December 18, 2014 titled "Pacific Biosciences Appoints Kathy Ordoñez to Board of Directors" (furnished and not filed herewith solely pursuant to Item 7.01).



Pacific Biosciences Appoints Kathy Ordoñez to Board of Directors

Industry Veteran Previously Served as SVP at Quest Diagnostics and CEO of Celera and of Roche Molecular Systems

MENLO PARK, California, USA – December 18, 2014 – Pacific Biosciences of California, Inc., (Nasdaq:PACB) provider of the PacBio® RS II Sequencing System, today announced that it has appointed industry veteran Kathy Ordoñez to its Board of Directors. Ordoñez has a 30 year history of leadership in the life sciences and diagnostics industries, including positions as Senior Vice President of Quest Diagnostics, Chief Executive Officer of Celera, founder of Celera Diagnostics, and President and Chief Executive Officer for Roche Molecular Systems.

In 2011 Ordoñez joined Quest as part of its acquisition of Celera and was responsible for the company's Diagnostic Solutions businesses, including diagnostic products, life insurer services, clinical trials and healthcare information technology products until she retired in 2013. Previously, she managed Quest's innovation pipeline and diagnostic products businesses, led the Celera business (including Berkeley HeartLab) and was responsible for driving the company's focus on personalizing disease management through diagnostic products and services. Prior to the acquisition by Quest, Ordoñez served as Chief Executive Officer of Celera and was a founder of Celera Diagnostics. Before joining Celera's parent company, Applera, in December 2000, Ordoñez held a number of senior positions over a 15-year period with Hoffmann La-Roche. She oversaw the formation of Roche Molecular Systems, serving as President and Chief Executive Officer, and led the application of polymerase chain reaction technology to the diagnostic, research and forensic fields.

"With its exquisite sensitivity and accuracy, long-read sequencing offers tremendous promise for future success in clinical diagnostics," said Kathy Ordoñez. "The remarkable advances Pacific Biosciences has demonstrated, which are already transforming biological studies in the research market, will be critical for driving the molecular diagnostics field forward. Demand for sequencing in that market is taking off, and I look forward to being involved with the company that stands to deliver unprecedented accuracy and completeness for such a critical application."

"Kathy is a highly respected life science and diagnostics executive and we are delighted that she's joining our Board," said Michael Hunkapiller, Chairman and Chief Executive Officer of Pacific Biosciences. "Her vision and guidance will be instrumental in shaping the next phase for PacBio as our products become more widely established both in the research market and, in the longer term, through our partnership with Roche Diagnostics."

About the PacBio RS II and SMRT Sequencing

Pacific Biosciences' SMRT Sequencing technology achieves the industry's longest read lengths, highest consensus accuracy, and the least degree of bias. These characteristics, combined with the ability to detect many types of DNA base modifications (e.g., methylation) as part of the sequencing process, make the PacBio RS II an essential tool for many scientists studying genetic and genomic variation. The PacBio platform provides a sequencing solution that can address a growing number of complex medical, agricultural, and industrial problems.

About Pacific Biosciences

Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers the PacBio RS II DNA Sequencing

System to help scientists solve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT) technology, the company's products enable: targeted sequencing to more comprehensively characterize genetic variations; *de novo* genome assembly to more fully identify, annotate, and decipher genomic structures; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. By providing access to information that was previously inaccessible, Pacific Biosciences enables scientists to increase their understanding of biological systems. More information is available at www.pacb.com

Contact:

For Pacific Biosciences:

Media:

Nicole Litchfield
415.793.6468
nicole@bioscribe.com

Investors:

Trevin Rard
650.521.8450
ir@pacificbiosciences.com
